MME and Alzheimer disease: These NSCs could be genetically modified to secrete neprilysin or other therapeutic transgenes (or both) for the treatment of AD and other neurodegenerative pathologies, such as Parkinson’s disease, stroke, and amyotrophic lateral sclerosis.